(Q38206711)

31 August 2017

Clinical trials of intravenous immunoglobulin for Alzheimer's disease (English)

1 reference

31 August 2017

0 references

Norman Relkin

1

1 reference

31 August 2017

24 April 2014

1 reference

Journal of Clinical Immunology

31 August 2017

1 reference

31 August 2017

34 Suppl 1

1 reference

31 August 2017

S74-9

1 reference

https://scigraph.springernature.com/pub.10.1007/s10875-014-0041-4

31 August 2017

0 references

cites work

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Intravenous immunoglobulin: exploiting the potential of natural antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Human antibodies reactive with beta-amyloid protein in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Autoantibodies to amyloid-beta and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Measurement of anti-beta amyloid antibodies in human blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Anti-amyloidogenic activity of IgGs contained in normal plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

A retrospective chart review of the tolerability and efficacy of intravenous immunoglobulin in the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0041-4

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24760112

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Is there a causal link between inflammation and dementia?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24760112

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10875-014-0041-4

1 reference

PubMed ID

24760112

Dimensions Publication ID

31 August 2017

0 references

1 reference

PubMed ID

24760112